LYZL1

Across TCGA pan-cancer cohorts, LYZL1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LYZL1 data layer compared with 16 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYZL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYZL1 expression acts as an unfavorable survival marker.

HNSC, BLCA, and ACC are the cancer types where LYZL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.119	0.759	<.001	42	view →
BLCA	DFS	Median	All	0.221	0.616	.028	18	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
LIHC	OS	Median	III,IV	0.051	0.738	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LYZL1–HNSC (OS)

Open the HNSC breakdown →